MedTrace Logo

A Clinical Trial of Patients With Melanoma

NCT02915666 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-05-15

No results posted yet for this study

Summary

This study is being done to find out if the combination of dabrafenib, trametinib and digoxin will lessen the side effects that you may experience and to measure your response and duration of response to the combination of drugs.

Conditions

Interventions

DRUG

Digoxin Combination

Digoxin 0.25 mg PO daily will be given for 8-week cycles

DRUG

Dabrafenib

dabrafenib 150mg PO twice daily for 8-week cycles

DRUG

Trametinib

trametinib 2 mg PO daily for 8-week cycles

Sponsors & Collaborators

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Arthur Frankel, MD · UT Southwestern.edu

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2017-07-17
Completion
2017-07-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02915666 on ClinicalTrials.gov